Navigation Links
Savient Pharmaceuticals to Present at The Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
Date:3/9/2009

EAST BRUNSWICK, N.J., March 9 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that Paul Hamelin, President of Savient Pharmaceuticals will be presenting at the upcoming Cowen and Company 29th Annual Healthcare Conference.

The presentation is scheduled to begin on Tuesday, March 17, 2009 at 8:45 a.m. Eastern Time. The Conference will be held at the Boston Marriott Copley Place in Boston, MA, March 16-19, 2009.

Individuals can listen to a live webcast of the presentation by logging on to the Investor Relations section of Savient Pharmaceuticals' Web site, http://www.savient.com. A replay of the webcast will be available on the Company's Web site for 30 days.

ABOUT SAVIENT PHARMACEUTICALS, INC.

Savient Pharmaceuticals, Inc. is a biopharmaceutical company engaged in developing and distributing pharmaceutical products that target unmet medical needs in both niche and broader markets. The Company's product development candidate, KRYSTEXXA(TM) (pegloticase) for treatment-failure gout, has reported positive Phase 1, 2 and 3 clinical data. Patient dosing in the Phase 3 clinical studies began in June 2006; patient enrollment was completed in March 2007; the Phase 3 clinical studies were completed in October 2007; the BLA was filed with the FDA in October 2008 and the FDA granted priority review status in December 2008. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA, formerly referred to as Puricase(R), from Duke University and Mountain View Pharmaceuticals, Inc. Savient's experienced management team is committed to advancing its pipeline and expanding its product portfolio by in-licensing late-stage compounds and exploring co-promotion and co-development opportunities that fit the Company's expertise in specialty pharmaceuticals and biopharmaceuticals with an initial focus in rheumatology. Savient also manufactures and supplies Oxandrin(R) (oxandrolone tablets, USP) CIII in the U.S. Further information on Savient can be accessed by visiting: http://www.savient.com.

SVNT-G


'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Savient Pharmaceuticals to Present at the Credit Suisse Phoenix Healthcare Conference on November 13th
2. Savients Board of Directors Forms a Board Committee to Oversee the Regulatory and Pre-Launch Activities for Pegloticase
3. Savient Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference on January 14th
4. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results
5. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
8. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
10. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... ... November 30, 2016 , ... The Fertility Centers ... as a Cigna Infertility Center of Excellence. The Cigna Center of Excellence recognizes ... an honor to be designated a Cigna Infertility Center of Excellence," said Fertility ...
(Date:11/30/2016)... , ... November 30, 2016 , ... "I hate when ... arm while brushing my teeth," said an inventor from Bridgewater, N.J. "I thought that ... develop this handy device." , He developed the patent-pending DEFLECTOR to prevent saliva and ...
(Date:11/30/2016)... FL (PRWEB) , ... November 30, 2016 , ... ... disorder and mental health treatment has announced the opening of a new eating ... partial hospitalization and intensive outpatient treatment for adults and adolescents, both males and ...
(Date:11/30/2016)... ... November 30, 2016 , ... In recent policy debates, increasing ... public policymakers and system stakeholders in many states. To help them understand this ... Index for Workers’ Compensation, Eighth Edition (MPI-WC) . , “If you are a ...
(Date:11/30/2016)... ... 30, 2016 , ... The Clinical Data Interchange Standards Consortium ... Guidance goes into effect next month. Sponsors whose studies start after December 17, ... Catalog. The current FDA Data Standards Catalog specifies the use of CDISC standards: ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... 2, 2016  UCB is pleased to announce that 12 scientific ... 70 th American Epilepsy Society (AES) Annual Meeting, which ... , USA. 1-12 Data being ... of VIMPAT ® (lacosamide) CV and BRIVIACT ® ... the current state of the union of epilepsy care and ...
(Date:12/2/2016)... , December 2, 2016 The iShares ... past losses following Trump,s victory early in November. Less ... fund managers are now predicting an uptick in M&A ... equities to see how they have fared at the ... ), Amicus Therapeutics Inc. (NASDAQ: FOLD ), ...
(Date:11/30/2016)... -- Research and Markets has announced the addition of ... report to their offering. ... Detachable coil embolization is a minimally ... detachable coil embolization treatment of cerebral aneurysms is less invasive and requires ... in the wall of an artery in the brain. This area bulges ...
Breaking Medicine Technology: